Reaction
Myoclonic Epilepsy reporting signals
As of the last recalculation, Myoclonic Epilepsy appears in 1,454 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is CLOBAZAM (PRR 96.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Clobazam | 148 | 96.5 | 97.1 |
| Valproic Acid | 157 | 79.8 | 80.2 |
| Phenobarbital | 72 | 74.8 | 75.1 |
| Levetiracetam In Sodium Chloride | 302 | 70.2 | 70.4 |
| Levetiracetam Oral | 302 | 70.2 | 70.4 |
| Levetiracetam Injection | 302 | 70.1 | 70.4 |
| Brivaracetam | 41 | 67.1 | 67.4 |
| Levetiracetam | 422 | 63.3 | 63.5 |
| Zonisamide | 62 | 62.6 | 62.9 |
| Lacosamide | 117 | 48.9 | 49.0 |
| Vigabatrin | 46 | 46.6 | 46.8 |
| Dutasteride | 25 | 44.8 | 44.9 |
| Tranexamic Acid | 27 | 44.3 | 44.4 |
| Cannabidiol | 68 | 43.6 | 43.7 |
| Oxcarbazepine | 89 | 41.7 | 41.8 |
| Phenytoin | 52 | 37.0 | 37.0 |
| Valproate Sodium | 49 | 35.1 | 35.2 |
| Lamotirigine | 150 | 33.3 | 33.4 |
| Lamotrigine Extended-Release | 150 | 33.3 | 33.4 |
| Lamotrigine Chewable Dispersible | 150 | 33.3 | 33.4 |
| Primidone | 22 | 31.4 | 31.4 |
| Cenobamate | 18 | 31.3 | 31.3 |
| Topiramate | 175 | 30.4 | 30.5 |
| Carbamazepine | 125 | 29.1 | 29.2 |
| Ketoprofen | 26 | 28.9 | 28.9 |
| Midazolam | 49 | 28.8 | 28.8 |
| Lamotrigine | 210 | 26.5 | 26.5 |
| Midazolam Hydrochloride | 38 | 20.7 | 20.7 |
| Propofol | 46 | 18.6 | 18.6 |
| Divalproex Sodium | 45 | 14.3 | 14.3 |
| Clonazepam | 134 | 13.1 | 13.1 |
| Norepinephrine | 8 | 10.8 | 10.8 |
| Lithium | 17 | 9.8 | 9.8 |
| Lithium Bromatum | 17 | 9.8 | 9.8 |
| Bupivacaine | 6 | 9.2 | 9.2 |
| Norepinephrine Bitartrate | 8 | 8.0 | 8.0 |
| Rocuronium Bromide | 5 | 6.1 | 6.1 |
| Botulinum Toxin Type A | 5 | 5.8 | 5.8 |
| Clozapine | 48 | 5.6 | 5.6 |
| Tapentadol Hydrochloride | 9 | 3.9 | 3.9 |